The research interests of the molecular imaging group are to provide technical capabilities and scientific expertise for integrating cutting-edge, multi-modality imaging into basic, translational, and clinical research. Our research activity is particularly focused on the use of integrated molecular imaging modalities, PET/CT and the very innovative fully hybrid PET/MRI system, with the use of different PET radiopharmaceuticals, for in vivo studies in different diseases.
Main fields of research include:
- the use of molecular imaging modalities for the evaluation of cancer patients, for risk stratification and monitoring response to therapy;
- the clinical and the predictive/prognostic impact of integrated molecular imaging modalities in neoplasms;
- the development of innovative PET tracer for a deep knowledge of cancer disease.
Overall aim of the research is the set-up of new non-invasive diagnostic imaging methods to be transferred in clinical practice for the optimization of diagnosis, prognosis and therapy in oncology.
Incerti E, Broggi S, Fodor A, Cuzzocrea M, Samanes Gajate AM, Mapelli P, Fiorino C, Dell'Oca I, Pasetti M, Cattaneo M, Calandrino R, Gianolli L, Di Muzio N, Picchio M*. FDG PET-derived parameters as prognostic tool in progressive malignant pleural mesothelioma treated patients. Eur J Nucl Med Mol Imaging. 2018 Jun 6.
Savi A, Incerti E, Fallanca F, Bettinardi V, Rossetti F, Monterisi C, Compierchio A, Negri G, Zannini P, Gianolli L, Picchio M*. First evaluation of PET based human biodistribution and dosimetry of 18F-FAZA, a tracer for imaging tumor hypoxia. J Nucl Med. 2017;58:1224-1229.
Incerti E, Tombetti E, Fallanca F, Baldissera EM, Alongi P, Tombolini E, Sartorelli S, Sabbadini MG, Papa M, De Cobelli F, Mason JC, Gianolli L, Manfredi A, Picchio M*. 18F-FDG PET reveals unique features of large vessel inflammation in patients with Takayasu's arteritis. Eur J Nucl Med Mol Imaging. 2017 Jul;44(7):1109-1118.
Evangelista L, Briganti A, Fanti S, Joniau S, Reske S, Schiavina R, Stief C, Thalmann GN, Picchio M. New Clinical Indications for (18)F/(11)C-choline, New Tracers for Positron Emission Tomography and a Promising Hybrid Device for Prostate Cancer Staging: A Systematic Review of the Literature. Eur Urol. 2016 Jul;70(1):161-75.
Incerti E, Fodor A, Mapelli P, Fiorino C, Alongi P, Kirienko M, Giovacchini G, Busnardo E, Gianolli L, Di Muzio N, Picchio M*. Radiation Treatment of Lymph Node Recurrence from Prostate Cancer: Is 11C-Choline PET/CT Predictive of Survival Outcomes? J Nucl Med. 2015 Dec;56(12):1836-42.
Mapelli P, Picchio M*. Initial prostate cancer diagnosis and disease staging-the role of choline-PET-CT. Nat Rev Urol. 2015 Sep;12(9):510-8.
Giovacchini G, Incerti E, Mapelli P, Kirienko M, Briganti A, Gandaglia G, Montorsi F, Gianolli L, Picchio M*. [11C]Choline PET/CT predicts survival in hormone-naive prostate cancer patients with biochemical failure after radical prostatectomy. Eur J Nucl Med Mol Imaging. 2015 May;42(6):877-84.
Picchio M*, Mapelli P, Panebianco V, Castellucci P, Incerti E, Briganti A, Gandaglia G, Kirienko M, Barchetti F, Nanni C, Montorsi F, Gianolli L, Fanti S. Imaging biomarkers in prostate cancer: role of PET/CT and MRI. Eur J Nucl Med Mol Imaging. 2015 Apr;42(4):644-55.
Picchio M*, Kirienko M, Mapelli P, Dell'Oca I, Villa E, Gallivanone F, Gianolli L, Messa C, Castiglioni I. Predictive value of pre-therapy (18)F-FDG PET/CT for the outcome of (18)F-FDG PET-guided radiotherapy in patients with head and neck cancer. Eur J Nucl Med Mol Imaging. 2014 Jan;41(1):21-31.
Picchio M*, Berardi G, Fodor A, Busnardo E, Crivellaro C, Giovacchini G, Fiorino C, Kirienko M, Incerti E, Messa C, Gianolli L, Di Muzio N. (11)C-Choline PET/CT as a guide to radiation treatment planning of lymph-node relapses in prostate cancer patients. Eur J Nucl Med Mol Imaging. 2014 Jul;41(7):1270-9.